Post Marketing Surveillance Study of Biphasic Insulin Aspart 30

Novo Nordisk

Status: Completed

Conditions: Diabetes Mellitus, Type 1; Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: biphasic insulin aspart 30

Study type: Observational

Funder types: Industry

Identifiers

NCT01536613

BIASP-1883

Details and patient eligibility

About

This study is conducted in Asia. The aim of this study is to review the safety and efficacy of biphasic insulin aspart 30 in post-marketing use.

Enrollment: 5,346 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Subjects with diabetes who did not have indications that are contraindicated in the product insert

Trial design

5,346 participants in 1 patient group

BIAsp 30 users

Treatment:

Drug: biphasic insulin aspart 30